TG Therapeutics (TGTX) News Today → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free TGTX Stock Alerts $17.42 -0.30 (-1.69%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 9, 2024 | americanbankingnews.comTG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 6, 2024 | americanbankingnews.comTG Therapeutics (NASDAQ:TGTX) Price Target Raised to $40.00May 6, 2024 | americanbankingnews.comTG Therapeutics (NASDAQ:TGTX) PT Raised to $49.00May 6, 2024 | americanbankingnews.comEquities Analysts Set Expectations for TG Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:TGTX)May 6, 2024 | americanbankingnews.comTG Therapeutics, Inc. (NASDAQ:TGTX) to Post Q2 2024 Earnings of ($0.04) Per Share, B. Riley ForecastsMay 3, 2024 | seekingalpha.comTG Therapeutics: Less Room For Doubt About BriumviMay 3, 2024 | finance.yahoo.comTG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comFY2025 EPS Estimates for TG Therapeutics, Inc. (NASDAQ:TGTX) Decreased by AnalystTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities researchers at B. Riley decreased their FY2025 earnings per share (EPS) estimates for shares of TG Therapeutics in a research note issued to investors on Wednesday, May 1st. B. Riley analyst M. Mamtani now anticipates that the biopharmaMay 3, 2024 | fool.comWhy TG Therapeutics Stock Was Rocketing Higher This WeekMay 3, 2024 | finance.yahoo.comRainbows and Unicorns: TG Therapeutics, Inc. (NASDAQ:TGTX) Analysts Just Became A Lot More OptimisticMay 2, 2024 | markets.businessinsider.comSell Rating on TG Therapeutics: Caution Amid Competitive Threats and Decelerating Prescription GrowthMay 2, 2024 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Price Target Raised to $49.00 at HC WainwrightHC Wainwright boosted their target price on TG Therapeutics from $45.00 to $49.00 and gave the stock a "buy" rating in a research report on Thursday.May 2, 2024 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Releases Earnings Results, Misses Estimates By $0.02 EPSTG Therapeutics (NASDAQ:TGTX - Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The firm had revenue of $63.47 million for the quarter, compared to the consensus estimate of $54.60 million. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. The firm's quarterly revenue was up 713.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.28) EPS.May 2, 2024 | finance.yahoo.comTG Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 2, 2024 | marketbeat.comQ2 2024 EPS Estimates for TG Therapeutics, Inc. Raised by B. Riley (NASDAQ:TGTX)TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Research analysts at B. Riley upped their Q2 2024 earnings estimates for shares of TG Therapeutics in a report issued on Tuesday, April 30th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will post earnings per sMay 2, 2024 | gurufocus.comQ1 2024 TG Therapeutics Inc Earnings Call TranscriptMay 1, 2024 | markets.businessinsider.comHold Rating on TG Therapeutics Amidst Strong Briumvi Launch and Competitive Market PressuresMay 1, 2024 | marketwatch.comTG Therapeutics Shares Rise 27% After 1Q Revenue BeatMay 1, 2024 | markets.businessinsider.comTG Therapeutics Inc. Q1 Loss decreases, but misses estimatesMay 1, 2024 | msn.comTG Therapeutics jumps as Q1 Briumvi sales top guidanceMay 1, 2024 | finance.yahoo.comTG Therapeutics Inc (TGTX) Surpasses Revenue Estimates in Q1 2024, Despite Widening Net LossMay 1, 2024 | marketbeat.comTG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Traders acquired 13,983 call options on the company. This is an increase of 88% compared to the average daily volume of 7,433 call options.May 1, 2024 | investorplace.comTGTX Stock Earnings: TG Therapeutics Misses EPS, Beats Revenue for Q1 2024May 1, 2024 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Forecasted to Post FY2026 Earnings of $1.60 Per ShareTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Research analysts at B. Riley cut their FY2026 earnings estimates for shares of TG Therapeutics in a note issued to investors on Tuesday, April 30th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will post earninMay 1, 2024 | globenewswire.comTG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsApril 30, 2024 | globenewswire.comTG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business UpdateApril 23, 2024 | markets.businessinsider.comBank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)April 18, 2024 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Stock Price Up 4.8%TG Therapeutics (NASDAQ:TGTX) Stock Price Up 4.8%April 18, 2024 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Earns "Overweight" Rating from JPMorgan Chase & Co.JPMorgan Chase & Co. reiterated an "overweight" rating and issued a $25.00 price target on shares of TG Therapeutics in a research note on Thursday.April 18, 2024 | globenewswire.comTG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingApril 18, 2024 | globenewswire.comTG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple SclerosisApril 17, 2024 | seekingalpha.comTG Therapeutics: The Cloud Over BriumviApril 15, 2024 | msn.comTG Posts Gains on Results of MS Drug TestApril 15, 2024 | globenewswire.comTG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingApril 15, 2024 | globenewswire.comTG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingApril 14, 2024 | nasdaq.comTG Therapeutics Breaks Below 200-Day Moving Average - Notable for TGTXApril 14, 2024 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from BrokeragesTG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the companApril 12, 2024 | seekingalpha.comTG Therapeutics: BRIUMVI Development Could Lead To Great ResultsMarch 20, 2024 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating onMarch 19, 2024 | finance.yahoo.comIs TG Therapeutics, Inc.'s (NASDAQ:TGTX) Recent Price Movement Underpinned By Its Weak Fundamentals?March 17, 2024 | investing.comTg therapeutics director sells shares worth over $79kMarch 16, 2024 | finance.yahoo.comTGTX Mar 2024 20.500 callMarch 16, 2024 | finance.yahoo.comTGTX Mar 2024 16.500 putMarch 16, 2024 | finance.yahoo.comTGTX Apr 2024 19.500 callMarch 16, 2024 | finance.yahoo.comTGTX Apr 2024 11.000 putMarch 15, 2024 | finance.yahoo.comTGTX Apr 2024 23.000 callMarch 15, 2024 | finance.yahoo.comTGTX Apr 2024 16.000 putMarch 15, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Purchases 145,667 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)Jacobs Levy Equity Management Inc. boosted its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 56.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 405,618 shares of the bioMarch 14, 2024 | insidertrades.comLaurence N. Charney Sells 22,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) StockMarch 8, 2024 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Shares Down 3.9% TG Therapeutics (NASDAQ:TGTX) Stock Price Down 3.9% Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address “Dollar Will Be Worth NOTHING” -Musk (Ad)Elon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher. Click here to claim your free seat ticket now. TGTX Media Mentions By Week TGTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TGTX News Sentiment▼1.080.55▲Average Medical News Sentiment TGTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TGTX Articles This Week▼15▲TGTX Articles Average Week Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MorphoSys News Bausch Health Companies News Corcept Therapeutics News MoonLake Immunotherapeutics News ACADIA Pharmaceuticals News Vera Therapeutics News Merus News Indivior News PTC Therapeutics News Avidity Biosciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TGTX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden FINISHED On June 13th?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe #1 Investment of the Decade… Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityWhy Is Gold On a MASSIVE rally? Huge AlertsUrgent Nvidia WarningAltimetryThe #1 Crypto for AIWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
